Thursday, June 11, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 54 of 1,261
  1. US 12258597

    Methods and compositions for therapeutic protein delivery

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  2. US 12258612

    Random heteropolymers preserve protein function in foreign environments

    The Regents of the University of California · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  3. US 12258627

    Kelch domain containing 7B (KLHDC7B) variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  4. US 12258412

    Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  5. US 12258366

    Bicyclic heteroaryl compounds and uses thereof

    Revolution Medicines, Inc. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  6. US 12258354

    AhR modulators

    IDEAYA Biosciences, Inc. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  7. US 12258372

    Recombinant vaccine against Marek's disease and Newcastle disease

    The United States of America, as represented by the Secretary of Agriculture · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  8. US 12258401

    Anti-CD47 combination therapy

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  9. WO 2025058008

    CONJUGUÉ ANTICORPS-MÉDICAMENT CONTENANT UN COMPOSÉ HÉTÉROCYCLIQUE AYANT POUR ACTIVITÉ L'INDUCTION DE LA DÉCOMPOSITION DE LA PROTÉINE KRAS MUTANTE G12D

    ASTELLAS PHARMA INC [JP] · Granted Mar 20, 2025 · Expires Mar 15, 2045

    granted
  10. US 12251449

    Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase

    The Board of Regents of the University of Texas System · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  11. US 12251432

    Biomarkers and immunogenic compositions for filarial parasites

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  12. US 12251445

    Gamma-hydroxybutyrate delivering compounds and processes for making and using them

    Zevra Therapeutics, Inc. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  13. US 12252714

    Halogenation of complex organic compounds

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  14. US 12252746

    Anti-CD46 antibodies and methods of use

    The Regents of the University of California · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  15. US 12252703

    Closed-ended linear duplex DNA for non-viral gene transfer

    VOYAGER THERAPEUTICS, INC. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  16. US 12252492

    Substituted fused pyrrolo-diazepinones and uses thereof

    Northwestern University · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  17. US 12252544

    Anti-CD63 antibodies, conjugates, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  18. US 12252522

    Myokines for treating cell proliferative and metabolic diseases and disorders

    Northwestern University · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  19. US 12252550

    Antibodies that bind to C1S and uses thereof

    DIANTHUS THERAPEUTICS OPCO, INC. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  20. US 12251387

    Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  21. US 12251397

    Cross-linked hyaluronic acids and combinations with PRP/BMC

    REGEN LAB SA · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  22. US 12252520

    Myosin 15 promoters and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  23. US 12252497

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  24. US 12251440

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.